J EFFERSO T J O URNA L OF PSYCHIATRY
a no m ia a nd a fluent a p has ia (I ). This corre la tes to th e neu rop a t hology that is g reates t in th e region s post erior to W ernick e's a rea . Eventu all y th e patient becom es mut e a nd ca nnot co m pre he nd (I) . Visuo sp atial deficit s a nd cog nit ion changes occur whi ch cor re la te to parietal and frontal injury (I). During th e end-stages of th e di sease, th e patient is unabl e to swa llow or mobilize a nd d ea th oft en occurs secondary to sepsis or d eh ydration . This a r t icle will focu s o n psyc hot ic symptoms in AD , but many ot he r ne uropsychi at ri c features lik e persona lity changes, d epression, viole nce, slee p d isturban ce, a nd wa nde ring a re com mon ( I) .
AD causes profound e mo tional suffe ring a nd eco nom ic burden for patient s and th ei r caregivers (3) . In 1997, th e pr eval en ce of AD in t he US was 2.32 million with a range of 1.09 to 4.58 million (4) . The lifetime risk of AD in the general population is roughly 15% (5) . Ab out 5% of individual s ove r 65 a nd 15-25% over 85 will deve lop AD (6) . In th e next 50 years th e pr eval en ce will a lmos t q uad r uple, meaning t hat I in 45 Am ericans will have th e dis eas e (4) . At pr esent , th e a n n ua l incid e nce is es t ima te d to be 360,000 (4) . In th e US, treating AD cos ts 100 billi on do llars a year, making it the third mos t expe ns ive di sease to treat a fter cancer and heart dis eas e (7) . Th e di rect a nd tot al cos ts of AD to curre n t a nd fu t ure gene ratio ns are proj ect ed to reach 536 billi on a nd 1.75 trillio n doll ars res pect ively (8) .
PSYCH OTIC SYMPTOMS
So me st udies ha ve shown th at a pp rox ima te ly 30-50% of a ll Alzheim er's patients will eve n t ua lly d evelop psych oti c fea t ures (9, 10) . Since a la rge number of AD patients will develop psychotic sym ptoms some t ime ove r th e course of t heir illne ss proper diagnosis a nd treatment is esse nt ia l (II ). Coope r, e t a i, noted th a t psychotic sym ptoms we re more pr evalent in advance d di sease, but th ey ca n prese nt at an y t im e during th e di sease co urse (9) . The link between psych otic sym ptoms a nd AD is well known . Dr. Aloi s Alzh eimer's initi al case rep ort descri bed sym ptoms of progressive m em ory loss, personality changes, d elusion al jealousy, para no ia , hall ucina t io ns, ve rba l outbursts, and di sori ent ation in a 5 1 yea r-old woma n (2, 12) . Nonpsychot ic disruptive behaviors su ch as motor restlessn ess, aggressive out bursts, pacing, and un cooperativeness are oft en mislab el ed as psych otic o r a re ass u me d to be re lat ed to th e underlying psychotic process (13) . Thus, in a ny AD patient t hat sudd enl y develops hallucinations or d elusions, other cond it ions need to be r uled out and includ e: drug intoxication, drug withdrawal, physical illn ess, d epression , an d delirium (3). Much of th e managem ent of Alzh eimer's di sease has focu sed o n controlling th ese nonpsychotic di sruptive beh avioral symptom s, in pa rt beca use t hey a re th e most di stressin g to ca re give rs a nd a re th e ones most likely to lead to in sti tutionalization (14) (15) (16) ). Yet , this man a gem ent ofte n lead s to t ri al s of antipsychoti cs in pat ients with out st rict ly defined psych otic processes ( 13) .
Delusions, Hallu cinations, and Misi dentifications
Th e ons et of psychosis in th e AD patient can occur a t a ny tim e, but is more lik ely in lat er sta ge s of th e di seas e (11,17). The specific sym p to ms a re wid e ran gi ng with th e most co m mo n being d elusions, hallucination s, a nd m iside ntificat ions (18, 19) . Raskind not ed that d elusions in AD t end to be " u ne la bo ra te d para noid beliefs based on th e underlying memory d eficit ", th ereby differing from th e "systematized complex d elusions of primary thought dis ord ers" (13) . In a re view of s tudies of psychotic symptoms a mong AD patients, d elusions were identifi ed in 10-73% of pat ie nt s, with most studies showing a range of 30 -38% ( 18) . Delusions of th e persecu tory typ e wer e th e most co m mon , acc oun t ing for 30 -33% of all delusions (18) (19) (20) . A st udy of 170 patients by Deutsch , e t a i, found fort y-three percent of pati en ts had de lusions with th e following fr equ encies by typ e: pers ecutory, 73%; reference, 14.9%; j eal ousy, 9.5%; g ra nd iosity, 1.4%; somatic, 1.4% (19) .
Th e second most fr equ ently occurring symptom of psych osis in AD is hallucinations. Mu lt ipl e studies have found th at visual hallucin ation s occur mor e oft en th an auditory or tactile typ es (18 ,19 ,21) . Deutsch , e t a l, rep ort ed th at 85 % of a ll hall ucinations were visual whi le Wragg a nd ] est e's review rep ort s a me dian fr equ en cy of 13% for a uditory hallucinations (18, 19) . This pattern of greate r vis ua l hallucina t ions is con siste n t with cond it ions like delirium, drug intoxication , drug withdrawal, or psychosis sec onda ry to a gen eral m edi cal cond it io n. Sc hizop hre nia, schizoaffective di sorder, a nd mo od di sorders with psychotic features typi call y pr esent with a uditory hallucinations. Thes e differences should provid e th e clini cian wit h helpful clu es in th e diagnostic work-up of th e psychotic patient.
A third type of psychotic symptom , misidentification synd romes or m ispe rceptions, hav e been not ed in many patients a nd a re concept ualize d as a fo r m of d elusion (20,22 ,23) . However, du e their unique charac te r, th ey ha ve been ca t egor ized apart from delusions a nd hallueinations (24) . Misperceptions result fro m a co m promised ca pacity to organ ize perceptual infor m a t ion in th e e nviro n me nt. Examples of m isidentifications a re th e bel ief that a stranger is in th e hous e, inability to recog nize on e 's own reflection, or a beli ef that television shows a re ac tually occ u rring in th e house . Burns, et ai, d escr ibed a fourth form of mi sid entification , t he e r rone ous iden tification of a fri end or relative for another person (23) . Mi sid entifi cat ions hav e be en report ed to occur in a bou t on e-qu art er to on e-third of AD pati en ts wit h a m edian of 23% (20 ,23,2 5) .
Associated Psychiatric Symptoms
Wh en psychosis is see n with other neuropsych iatri c sym pto ms lik e dep ression and agitation, the patient is more likely to be in th e advan ced st a ges of th e disease and mo re diffi cu lt for t he ca re give rs to manage (26) . Levy, et ai , lon gitudinall y exa mined re curre nc e ra t es of neuropsychiat ri c symptom s in 181 patients with AD over a I-yea r pe riod ( 17) . Recurrence rat es were 95% for psych osis, 93% for ag itation, and 85 % for depression. Of interest, th e patients that displayed multipl e sym pto ms at any point during t he study showed greater recurren ce rat es of sym pto ms during th e remaining pa rt of t he study. Also , if a patient di splayed psycho sis upon initi al evalua t io n, t hey were more likely to d ispl ay agitation and a n accel er at ed cog ni t ive decline over th e next year. T he patients in t he 76-87 yea r group were not ed to have more psyc ho t ic symptoms bu t less d ep ression a nd agita tio n than younge r pati en ts.
Wom en were found to di spl ay more neuropsychi at ric sym pto ms t han the men. This st udy co nclude d th at once sym pto ms like psych osis, depression, an d agitation begin that th ey fr equ ently recur and th at vari an ces ex ist by sex a nd age ( 17) .
Mu ch of th e lit erature re po rts th at psych otic sym ptoms are associated with in cr eased cognitive decline (27) (28) (29) (30) (31) (32) . U nde rs ta nd ing th e progression of cognitive declin e in Alzh eimer's di sease a nd it s associat ion wit h psych osis is im port a n t be cause psychotic symptoms a re one of th e prima ry re aso ns for instit u tion al iza tion (15, 21) . In suppo rt of this, a st udy of 236 patients by St ern, et a i, foun d t hat patients who d em on strat ed psychotic symptoms a t th e initi al vis it, incr eased thei r re lative risk or rea ching an in stitution al ca re rating eq u ivale n t to a nu rsin g hom e by a factor of 1.5 (33) . Lerner, e t ai, found th at Alzh eimer's pati ents wit h visua l ha llucinations performed worse on Mini-M ent al Sta t us Examinations an d d ispl a yed more verbal outbursts, d elusions, and paranoid ideat ion than those withou t hallu cina tions (29) . In cont ras t to th es e findings, Wragg and] est e, in th eir review of psych osis in AD, cit e seve ra l studies that found d elusions were more likel y in pa tients wit h high e r cog nitive scores (18) . The expla na tion give n is th at so me level of cogn it ion is necessary for delusions to occ ur (18, 32) . T eri , e t a l, fou nd no d iffere nce in hallucination fr equ en cy a t diffe ring levels of cog nitive fun ct ioning (34) .
The rel ation ship between pa rticul ar psych oti c sym p to ms and associat ed behavior s in Alzh ei m er's patie nt s has also been exa m ine d (9, 19, 29, 35) . Cooper, et a i, rep orted that AD pati ents with psych osis we re twice as likely to be agitat ed (9) . Lerner, e t a i, found th at visua l hallucin ation s we re pos itive ly associat ed with agita tion a nd paranoid sym pto ms (29) . Other be hav ioral signs and symptom s associa te d with visua l hallucination s include d a udi tory halluci nat ions, verbal outburst s, delusions, a nd paran oid ideation (29) . In a rep ort by Gi lley, e t aI, hallucin ations were associa te d with ir ritability, di sinhibition , ex trapyramida l symptoms, agitation, a nd d elusions (35) . Furth er, Deu tch , et a i, co ncl uded th at th e pr esence or d elu sions and mi sid entifi cation s m ight be pr edi cti ve of ph ysical aggression (19) . Cl early, psychotic symptom s are as socia te d with a wid e ra nge of beh avior a l reactions in Alzh eimer's patients.
Psychosis and Genetics
Recently there has been a focus on th e ge ne tics of AD, whi ch is a gen et ica lly het erogen eous disorder associat ed with 3 det erminative ge nes a nd I susceptibility risk ge ne (5). The det erminative ge ne s are of th e aut osom al dominant type fou nd on ch ro mosome s I, 14, a nd 2 1 are ea rly-onse t form s th at manifest in t he 40s a nd 50s, a nd acco u nt for a bout 5% of all ca ses (5) . In 1993, a n a po lipoprote in E (APOE) eps ilon 4 a lle le on ch romosome 19 was di scove red to have susce ptib ility to lat e-onset AD by incr easing risk a nd d ecr ea sin g age of onse t (5, 36) . Th e amyloid pr ecursor prot ein (APP) ge ne is found on chr om osome 2 1 is b rok e n down to a protein , Bet a-amyloid , t hat is t he major cons tit ue n t of se nile plaqu es (6) . Th us, persons with Down 's Synd ro me over 40 a lmos t uni versall y have pa t hological fea tures of AD at a u to psy (5) . About 40% of pati ents with AD have a posi tive fam ily histor y for th e di sorder, but th e 50 % concordance rat e in mon ozygotic twins studies po ints to e nviron me nta l factors (6, 36) . Environmental risk st udies, howeve r, have given varied results wh en exa m in ing th e a re as of head t rauma , sex, a nd toxins ( 1,5).
Recent research has focus ed on th e relationship between th e APOE genotype and psyc hiatric symptoms to includ e psychosis (37-4 1). A st udy by H a rwood, et ai, th at exam ine d 50 I patients with probabl e or possibl e AD found a n elevated risk for psych osis a mong th ose with th e eps ilon 4 alle le (3 7) . Several ot her st ud ies have found no cor re la tion between th e epsilon 4 alle le a nd psych osis (38) (39) (40) . Sweet, et ai, exam ine d th e dopamine receptor ge ne polymorphism s DRD I, DRD2, DRD 3, and DRD4 for associa tions with th e presence of psychosis in AD (42) . They fou nd more psychosis in whit e pati ents with DRDI B21B 2 homozygosit y (42). Also, psyc hosis was more fr equ ent in all AD pati ents with DRD3 1/ 101' 2/2 hom ozygosit y (42) . This study co ncl ude d that ge ne tic va ria tion in DRD I a nd DRD3 ge nes mi ght mod ify the course of AD, pr edi sposin g to th e developm ent of psych otic or aggressive sym ptoms (42) .
NEURO IMAG I T G
Ne u ro imaging via compu te d tomogr aphy (C T) or m agn etic resona nce imaging (M RI) is not di agn osti c for AD , as AD produces no pathogn om oni c cha nges t hat are see n on conve n tiona l neuroimaging (1,43). However, many expe rts recom mend ba selin e imaging to ru le out treatable form s of d em entia. Wh en used , non -cont rast com pu te d tomography to find a t ro phy or diffu se whi te matt er is usu all y sufficient (43) . le u roa na to rnica l corre la te s of seve r ity of illn ess a nd prese nt a ti on of be havioral sym ptoms have lon g been known in AD . Zubenko, et ai, showed th a t psych ot ic AD patients had increased den sities of seni le plaqu es in th e pro subiculum of t he hippocampus and incr eased d ensities of neurofibri llary tangles in th e middl e fron tal co rte x wh en com pa re d to non-psych otic AD patients a t a uto psy (44) . Thei r findings a re int eresting to not e as ch ro nic idiopathic psych osis of ea rl ie r life is accompanied by decr eased b lood flow and glucose m etabolism in th e frontal co rtex a long wit h ce ll loss in t he hippocampus (44) .
Posit ron e m ission tomography (PET) a nd sing le e m ission co m pu te d tom ogr aph y (SPEC T) allow for visualization of brain a bnor malit ies via new a pproaches to conve n tional im aging ( 1,44) . In th e future PET a nd SPECT may a llow for early pr edi ction of whi ch patients will d evelop psychosis. In ge neral, AD ca uses red uced perfusion or m etabolism in th e region of th e ternporo-pari eto-occipital j unct ion as vis ualized by SPECT or PET ( 1,45). AD patients show redu ced perfusion a nd m et abolism in th e co rtica l associa tion area s that spa res th e ba sal ga ng lia, th al a mu s, ce re be llu m , a nd primary corte x (3) . Organic psych osis a nd sch izophre nia have been hypoth esiz ed to be th e result of temporal, pa ri et al , a nd front al lob e dysfun ct ion ; how eve r, th e ne u ro a na tom ic substrat e for hallucin ations a nd delu sion s is unknown at this tim e ( 10). Yet , many studies have found that delusion s cor re la te with temporal and fronta l lob e dysfuncti on on PET a nd SPEC T (46). Kotrl a, et a i, exam ine d th e hypoth esis th at psych osis in pati ents with AD was associated with ce re bra l dysfunction in both th e front al and th e parietal lob es, since virt ua lly all AD patients have temporal lobe pathology ( 10). They found that delu sional pati ents had hypope rfusion of t he left fronta l lobe wh ile hallucina ting pa tients had hypoperfusion in th e parietal lobes. This st udy conclude d that psych otic pat ients with AD had ce re bra l blood flow deficits sign ifican tly different fro m nonpsych otic patients with AD (10) . Thus, AD m ay provid e a model for investigation of th e man ifesta tions of th e ce re bra l dysfunction that produces psychosis (10).
MA T AGEMEf\'T
If th ere is mini m al potential danger to t he patien t or ot hers, reassurance and di stracti on is th e t reat ment of choice for psych ot ic AD pa tie n ts (47) . If agitation or viole n t beh avior is pr esent a nd places the pat ient or caregivers at risk for harm , ph a rmacologic treatm ent a long wit h one -on-one care is ofte n req ui red. In som e cas es restraints may be required but ongo ing usc m ust be j ust ified. Th e number on e goal is pati ent and st aff sa fe ty a nd com fort. Agit ation , which ofte n accompanies psychosis, may be du e to an undiagnosed cond ition suc h as pain , a nx ie ty, hunge r, cons tipation, or fear of a ba ndo n me n t. Treatm ent here shou ld focu s on reassu rance, att ending to unm et needs a nd correcting th e und erlyin g cond it ion wit h ca re ful medi ca l eva luation (4 7,48).
Neuroleptics
The primary m an agem ent of psychosis in Alzhe ime r's d isease ha s t rad itiona lly reli ed up on neurol epti c m edi cation s th at have lon g been used to target delusion s, hallucin ations, and ag ita tion ( 14, 15) . The usc of neu rol ept ics in th e elderly population is complex because adverse effec ts arc com mo n a nd se nsitivity to dru g-drug int eractions is incr eas ed (49). In thi s popul ation th e adve rse effects of grea test con cern includ e orthostatic hypot ention, delirium, ex t ra-pyra m idal symptoms (EPS), tardive dyskin esia, urinary ret ention , a nd gla uco ma. Sunde rla nd noted that elde rly dem ented patients may be more se ns itive to th e adve rse effects of neurolep tic drugs and may require lower do ses than non-dem ent ed controls ( I I) . Of particular not e is that th e risk for tardive dyskin esia ('I'D) is 50% in th ose 65 years or older eve n with shor t-te rm us e (49) . Traditionall y, low do ses of high-pot en cy ag e n ts like hal ope ridol have been th e initial drugs of choice (50, 51 ) . Halop eridol may ca use parkinsonism, making monitoring for bradykin esia, rigidity, a nd sia lorrhea necessa ry (52) . A randomized, pla cebo-controlled do se-comparison trial of hal op eridol for psyc hosis a nd disruptive behaviors wa s cond ucte d recently by Devan and (53). T his study indicated a favorabl e th erapeutic profile for doses of 2-3 rug/day of hal ope ridol, but a subg roup of pati ents developed EPS (53 ) . The use of low-pot en cy neuroleptics sho uld ge ne ra lly be avoide d du e to th ei r anti-ch olinergic effects ( 15) . Also, patients with Alzh eim er 's di sea se are a t high risk for fall s or m ay have chronic obst ru cti ve lung di sease, urinary ret ention , cons tipa tion, or ot her con ditions in whi ch lowpot en cy age n ts a rc con traindica te d ( 14, 15) .
Th e d evelopment of newer m edi cations suc h as risp eridon e and olan zapine, hav e mad e the drug of initial choice for psychosis a n a rea of d eb at e (54) . Med icat ions such as risperidone hav e gained favor in th e treatm ent of sch izop hrenia a nd ot her psychotic disorders largely because of safer side -effec t pr ofiles. Risp eridone has receiv ed support from so me ge ria t ric clinicians wh o re po rt effec tive ne ss at very low dos es (0.5-2.0 m g/d ay) (47, 55 ) . Seve ral st ud ies have shown rispe ridon e to be effectiv e in reducing psych oti c sym ptom s a mo ng d em ented pati ents (25, 49, 56) . Kat z, et ai , exa m ine d 625 institutionalized patients with d em entia (73% wit h AD) and significa n t psychosis or beh avioral sym pto ms in orde r to eva lua te t he efficacy and sa fe ty of risp eridon e in thi s popul ation (56) . Th e pat ients were randomized in a doubl e-bl ind , pl aceb o-cont roll ed fash ion to pl aceb o, low-dose (0.5 mg/day), mediumdose ( I mg /day), or h igh-dose (2 mg/day) risperido ne for 12 weeks (56) . The study concl ude d th at risp eridon e significa n tly im proved sym ptoms of psychosis in severe d em entia wit h I rug/d ay being an ap propriate dose for most patients (56) . With regards to sa fety, th e fre q ue ncy of EP S was not significan tly great er t han placeb o for those receivin g I rug/d ay of risp eridon e (56) . C lozapine may prove usefu l for tho se patients se ns itive to EPS, but du e to it s high cos t, wee kly to biweekl y blood monitoring, and risk for ag ra nu locytosis, it s us e ma y be limit ed in t his popula tion (55) . Tariot reviewed reports of clozapin e use in psych oti c d em ent ed patie nts and found a mixed pict ure in terms of efficacy a nd side effec ts wit h som e report s showing a reducti on in psych osis a nd agita tion while ot he rs showing no ben efit (25) . T he elde rly a re more susce ptible to bru isin g, se da tion, hypote n tion, confus ion, and othe r a n ti-cho line rg ic effec ts of clozapine . Most of t he published lit era t u re for t he use of clozapine in thi s population is based on ope n tria ls, chart reviews, a nd case reports. Thus, th ere is a lack of co n trolled tri al s.
Ol an zapine a nd quetiapine a re newer drugs th at show sim ilar efficacy to co nve nt iona l neurol eptics a nd do not require blood monitoring (47) . O la nza pine a nd quetiapine a re not significantly different from placebo in regards to EPS pr ofiles a nd ha ve lower risk of tardive dysk en esia. Olanzapine has been shown to be generally sa fe in sch izoph re n ic populations but m ay be acco mpa nied by mi ld sedation, som e a n ti-cho line rg ic effec ts, di zzin ess a nd weight gai n (57) . Quetia pi ne has been sh own to ca use no cha nges in he matological or ECG profi les , required no blood monitoring, a nd di spl ays low EPS profiles (58) . Howeve r, q ue tiapin e demonstrat es substa n tia l hist amin ic recep tor blockad e with resulting dizziness, postura l hypot en sion, somnolen ce, a nd we igh t ga in in some pati e nt s (59) . An in terim analysis at 12 we eks of an ongo ing one yea r, ope n trial of qu etiapine in 151 elde rly pat ien ts wit h d e me nt ia (75 patients with AD ) and mixed beh avioral problem s, including psych osis, was recently perform ed (60) . Patients received 25 m g to 800 mg/day of qu etiapin e (median do se = 100 mg/day) with 6% of pati ents showing EPS. This st udy co ncl uded th a t qu etiapine was well tolerat ed a nd associa te d wit h improvem ent in elde rly pat ie nt s with psychotic di sorders (60) .
Impl em ent ation a nd dosing of a n ti-psyc ho tics agents is com plex. In general, non -pharm acologic a lte rnatives sho u ld be atte m p te d first du e to large num bers of pot ential side -e ffec ts of a nti-psyc ho tics . Gen erall y, side -e ffec t profil es dictat e t he cho ice of age n t a nd ca n be minimized by usin g th e lowest effect ive dose (47) . Dosing sho uld ge ne ra lly be st art ed at about Ij { to 1j2 th e usual ad ult dose a nd risks ve rs us ben efit s mu st be reassessed on a n on going basis. For exa mp le with halop eridol, a sta rt ing dos e of I mg /day with gradual, upward dos e titration is recommended (53) . U se of anticholinergi c age n ts should be avoid ed . Som e authors sugges t it may be more beneficial to sche d ule medi cation in a n t icipa t ion of be havior rather than reacting to symptoms with as need ed m edi cation orders (5 1). In ot he r words, identify sp ecific times of d ay or ac t ivit ies that pr ecipitat e ce r tain unwant ed be havior and m edi cat e about on e hour prior to this tim e (25) . Mo st co m mo n ly, t his wou ld be at ni ght to help fost e r slee p and treat a ny behavior al pr obl ems th at oft en peak at that tim e (47) .
Alternative Agents
A wide variety of o ther ag ents have been used with som e succe ss, including lithium, bet a-block ers, se lect ive serotoni n reupta ke in hibitors (SSRI's), trazodon e, bu spiron e, benzodi a zapines, a nd a nti -convulsants (47,50,5 1) . G e nerally, th es e agents have been used to t reat agit ation o r aggress ion ra t her t han used to treat psychosis pe r se . For behavioral con t rol, th e use of t ra zod o ne seems prom ising in se ve ra l st ud ies ( I I). Tra zod on e give n a t bedtime reduces nigh tt im e ag itation, whil e lower doses during th e day help with daytim e ag itat ion (52) . Preli m ina ry dat a sugge st SSR I's may help a llev ia te ag itat io n (47) . Ant i-convulsants may be indicat ed for mildly agita te d pati en ts who do not res po nd to an ti-psychotic m edi cation (4 7). Althou gh a n t i-co nvu lsan ts have fewer side -effects, blood monitoring is required . Ben zod ia zepines have been show n to cont ro l behavioral prob lems bett er th a n placebo but not as we ll as a nt i-psyc ho tics (47) . Be nzod ia ze pi nes arc oft en give n in conj u nc t ion wit h a nt i-psyc ho t ics but sho u ld be used wit h ca u tion in Alzh eimer's patients. G ene rall y, th e use of low-d ose, sh ort-acting agen ts with no active metabolites (i.e.-oxazepam or loraz epam ) are th e initial d ru gs of cho ice . Unfortun at ely, side effec ts suc h as a taxia, co nfus io n, a nd seda t ion ma y place th e pat ient at risk for fa lls . No ne of th e a lte rnative age n ts have been foun d to target psychosis but may be helpful in treating associa te d agita t ion in a ppropria te cases (49) .
C u m mings describes th e t h ree ph armacologic treatments in us e at pr esent in th e t reatm ent of AD: di sease-mod ifyin g agents, agen ts to manage symptoms of cog nit ive deficit s, a nd psychotropic age nts for beh avioral dis turbances (52) . Both th e clinical lit erature a nd th e public have e m braced vitamin E, est roge n, cholinest erase inhibitors and ging ko biloba as possibl e di sease-m odi fying agents or t rea t m e n ts for cog nitive d eficits (52) . The pr esent st ra tegy is to treat m ild-t o-m od era t el y affect ed patients with vitamin E and a choline ste rase inhibitor (i.e.-don ep ezil ). Th e us e of cho lines te rase inhibitors a ppears to slow th e ra t e of cognit ive decline in som e pati ents a nd may help to reduce hallucin ation s and d el usio ns (52) . P rincipa l limitat io ns of t hese age nts include th eir expe nse a nd ina bili ty to stop th e course of th e disease. In lat e r stages of th e di sease, psych ot ro pic agents arc usually necessary and prolon ga tion of th e illn ess wit h vitam in E may no lo nge r be a th erapeutic goal (5 2). Post-m en op au sal wome n on es trogen d evelop AD less often, and estrogen give n to wom en wh o a lready have AD show reduced cognit ive effects (52) . No studies to dat e show wh ether or no t those give n es troge n are less lik el y to deve lop psychotic symptom s. Th ere is so me evide nce th at individu al s ad m iniste re d non-s teroidal a n t i-infla m m a to ry drugs (NSAIDS) demonstrat e lowe r incid en ce of AD, but littl e PSYCHOSIS IN A LZ H E I~IE R'S DISEASE prosp ective dat a is availa ble (52) . No evide nce to dat e has suggest ed th e use of NSAIDS prevents th e d evel opment of psychosis in AD pati ents.
Non-pharmacologic Approaches
The efficacy of nonpharmacologic interve n tio ns In th e t rea t me n t of psycho sis remains to be es tablis he d a nd in many in st ances will ha ve on ly limit ed ben efit (53, 6 1,62 ) . Yet , so me so urces st ress th at behavioral t herapies are important in th e m an agem ent of AD as th ey m ay reduce th e occ u r re nce of psych ot ic symptoms in pati ents a nd decr ease st ress in ca regive rs (I 4, 15). T ypi call y, specific behavioral techniqu es a re organized a ro und th ree ce nt ral th em es: I) mo d ification of th e ph ysica l e nviro n me nt to minimize ex t ra ne ous st im uli a nd maxi m ize pat ie nt di gnity a nd sa fe ty; 2) training of ca regive rs to com m u nica te effect ively wit h AD pati ents; a nd 3) pr ovision of e mot ional support, com m u nity resour ce information , a nd respit e ac t ivit ies for ca regive rs . Modifyin g th e e nviro nmen t may be qu it e simpl e (26) . For exa m ple, it is oft en he lp ful to a r ra nge t he hom e in a n or de rly an d syst ema tic way wit h not es to remind th e patient wh e re things are (26) . Good lighting, carefu l placem ent of mirrors, a nd ab sence of tel evision s or radi os can help re d uce d elusions a nd mi sid entifications (20) . Sin ce visio n a nd hearing impairmen t often contribut e to problems for AD pat ients it is important to e ns u re t he pati ent 's glasses and hearing a ids a re in goo d o rde r. Assisting non -profession a l ca regivers is vital in th e t rea t me nt of AD , as non -profession al s provid e 80% of overall care (26) . T eaching fami ly m embers to co m m unica te effec t ive ly wit h th e A D pat ient ca n a me lio ra te some of th e fru stration pat ients ma y evo ke . Refer ring family m embers to th e local chapter of th e [at ion a l Alzh eimer's D isease & Rel a t ed D isorde rs Association ca n im prove th ei r access to co m m unity resources a nd ove ra ll qualit y of care (26, 52) .
If t he pati ent reaches th e point whe re in stitutionali za t ion beco mes necessary, specia l ca re units a re oft en ava ila ble (20, 63) . These uni ts provide a safe, nonthreat ening env iro n me nt in whi ch ir rel evan t st im uli are reduced (20) . In recen t years suc h unit s have becom e incr easin gly avai la ble a nd may slow th e declin e of fu nc t iona l ca pacity . A rece n t study of 1228 resi dents in 48 fa cilities with specia l ca re unit s demon strat ed no stat ist ica lly sig nifica nt di ffere nces in speed of d eclin e from tradition al unit s; howeve r, th e aut hors concl uded that th es e units mi ght pr ovid e unm easured ben efits to famili es a nd resid ents by improving overa ll q uality of life (63) .
CONC LUSIONS
Th e associa t ion bet ween psych ot ic sym pto ms an d Alzhe ime r's d isease is well know n, a nd th ese sym ptoms are di st ressi ng to pa ti ents, ca re give rs, and clinicians. It is also know n th at de lusions, hallucination s, a nd m iside n t ifica t ions occur co m monly among AD pa t ie nts a nd a re associate d wit h sig nificant morbidity. Controversy re m ains as to whet her or no t psych ot ic sym ptoms lead to a more ra pid cog nit ive declin e, but most researc he rs agree th at psych osis is pos itively associa ted with agita t ion a nd aggression (9, 19, 29, 35) . C u r re nt m an agem ent of psych osis ce nters on use of a nt i-psychotic medi cation , behavioral th erapy, and family ed ucat ion ( 14, 15,20,5 0,5 1). T here is a pau city of scientific lit erature on th e nonpharm acologic a pproaches to th e managem ent of psychosis in AD and th eir overall efficacy is yet to be proven (53, 62) . W ith regards to ph armacologic m anagem ent, th e use a nd developm e nt of newe r m ed ica t io ns with fewer side -e ffec ts a ppears promisin g (47) . At th e pr esent ti m e t he litera ture lacks a numbe r of con t rolle d st udies on th e a typ ica l an t i-psyc hotics in AD patient s, but it a ppea rs t ha t more st udies are for t hco m ing. Th e effe cts of spec ia l ca re uni ts on fu nc t ional outco me in AD is a n a rea th at requires more investigation (63) . C ur re nt Research is now usin g fu nc t io na l neuroimaging to exam in e AD, but neuroan at omic cor re la tes of psych osis in AD rem ain largely unknown (3, 10) . Articl es addressin g po ssibl e differen ces bet ween psych oti c sym p to ms in t he fam ilia l form s a nd th e suscept ibility form of AD were not located in thi s review. Th e hop e is t hat more will be di scovered about possibl e ge ne tic co rre la tes to th e neu ropsychi at ri c symptom s of AD in th e near future. It is a ppa re nt fro m this review th a t m uch wor k remains in th e exam ina tion of th e di sease th at Alzhe im er describ ed as, "a pecu liar di sease of th e ce re bra l co r t ex" (2) .
